# 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

> **NCT01583842** · EARLY_PHASE1 · TERMINATED · sponsor: **Miguel Pampaloni** · enrollment: 10 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)
- **DRUG:** 124I-MIBG (carrier added)
- **PROCEDURE:** Positron Emission Tomography (PET) /Computerized tomography (CT)

## Key facts

- **NCT ID:** NCT01583842
- **Lead sponsor:** Miguel Pampaloni
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04-09
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-02-25
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2021-05-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583842, "124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01583842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*